Also, we demonstrate the importance of an SGLT2 inhibitor in patients undergoing CABG by showing that it reduces ischemic risk (by decreasing the H-FABP levels) in patients with/without T2DM and with/without CKD. This evidence concerns the gene FABP3 and type 2 diabetes mellitus.